Follow us on Twitter
twitter icon@FreshPatents


Vaccination patents

      

This page is updated frequently with new Vaccination-related patent applications.




 Tumor vaccination involving a humoral immune response against self-proteins patent thumbnailTumor vaccination involving a humoral immune response against self-proteins
The present invention relates to tumor immunotherapy, in particular to tumor vaccination, using chimeric proteins comprising all or a portion of a hepatitis b virus core antigen protein and an amino acid sequence comprising an epitope derived from the extracellular portion of a tumor-associated antigen. In particular, the present invention provides virus-like particles comprising said chimeric proteins, which are useful for eliciting a humoral immune response in a subject against the tumor-associated antigen, in particular against cells carrying said tumor-associated antigen on their surface, wherein the tumor-associated antigen is a self-protein in said subject..
Biontech Ag


 Methods and compositions for producing an adenovirus vector for use with multiple vaccinations patent thumbnailMethods and compositions for producing an adenovirus vector for use with multiple vaccinations
Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided.. .
Etubics Corporation


 Sequential administration of a replication defective adenovirus vector in vaccination protocols patent thumbnailSequential administration of a replication defective adenovirus vector in vaccination protocols
Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided.. .
Etubics Corporation


 Histone deacetylase 6 inhibition for enhancing t-cell function during anti-tumor response and tumor-peptide vaccination patent thumbnailHistone deacetylase 6 inhibition for enhancing t-cell function during anti-tumor response and tumor-peptide vaccination
Disclosed are methods whereby an effective amount of a hdac6 inhibitor is used to activate a subjects t-cell response to tumor or tumor vaccine. Methods of using hdac6 inhibitors to increase a subjects anti-tumor immune response, alone or in conjunction with other tumor treatments, are also disclosed..
H. Lee Moffitt Cancer Center And Research Institute, Inc.


 Method to enhance an immune response of nucleic acid vaccination patent thumbnailMethod to enhance an immune response of nucleic acid vaccination
A composition comprising liposomes associated with a nucleic acid operatively encoding an antigenic protein and with an assistor protein, wherein the assistor protein shares at least one epitope with the antigenic protein, and wherein the nucleic acid and said assistor protein are associated with the same liposomes is described. The composition provides an improved immune response compared to mixtures of liposomes some of which are associated with the nucleic acid and some of which are associated with the assistor protein..
Lipoxen Technologies Limited


 Vaccine patent thumbnailVaccine
The present invention relates to a pharmaceutical combination of compositions for use in the treatment or prevention of a disease having cells bearing a target antigen as a vaccine and to a method for vaccination of a mammal, especially of a human for raising a cellular immune response directed against cells of the mammalian recipient, especially human recipient, which cells express a target antigen. The target antigen can e.g.
Medizinische Hoschschule Hannover


 Lipoteichoic acid from lactobacilli as a potent immune stimulatory adjuvant for vaccine development patent thumbnailLipoteichoic acid from lactobacilli as a potent immune stimulatory adjuvant for vaccine development
The present invention provides compositions and methods useful for vaccination and generating cd8+ t lymphocyte immune memory against one or more antigens utilizing lipoteichoic acid.. .
University Of Florida Research Foundation, Incorporated


 Formulations that provide support during vaccinations and adaptive immune system response patent thumbnailFormulations that provide support during vaccinations and adaptive immune system response
The present invention provides formulations that support an individuals body during routine vaccination and adaptive immune response. The individuals who can benefit front these formulations are infants, children and adults.

 Artificial nucleic acid molecules patent thumbnailArtificial nucleic acid molecules
The invention relates to an artificial nucleic acid molecule comprising at least one open reading frame and at least one 3′-untranslated region element (3′-utr) element comprising a nucleic acid sequence which is derived from the 3′-utr of a ribosomal protein gene. The invention further relates to the use of such an artificial nucleic acid molecule in gene therapy and/or genetic vaccination.
Curevac Ag


 Pcv2 orf2 protein variant and virus like particles composed thereof patent thumbnailPcv2 orf2 protein variant and virus like particles composed thereof
vaccination methods to control pcv2 infection with different pcv2 subtypes are disclosed. Specifically, a pcv2 subtype b (pcv2b) orf2 proteins or immunogenic compositions comprising a pcv2b orf2 protein are used in a method for the treatment or prevention of an infection with pcv2 of the same pcv2b and/or different subtype; the reduction, prevention or treatment of clinical signs caused by an infection with pcv2 of the same pcv2b or a different subtype; and/or the prevention or treatment of a disease caused by an infection with pcv2 of the same pcv2b and/or a different subtype.
Boehringer Ingelheim Vetmedica, Inc.


Human sirpa transgenic animals and their methods of use

The invention relates generally to compositions and methods of using transgenic non-human animals expressing human sirpα that are engrafted with a human hematopoietic system. In various embodiments, the human hematopoietic system engrafted, human sirpα transgenic non-human animals of the invention are useful as systems for the in vivo evaluation of the growth and differentiation of hematopoietic and immune cells, for the in vivo assessment of an immune response, for the in vivo evaluation of vaccines and vaccination regimens, for in vivo production and collection of immune mediators, including human antibodies, and for use in testing the effect of agents that modulate hematopoietic and immune cell function..
Yale University

Heat inactivated poxvirus improves vaccination results

Compositions including a heat-inactivated poxvirus, such as vaccinia virus, that induces one or more interferons in a vaccine recipient. The compositions may further include one or more live vaccine vectors and non-replicating vaccine components.
Arizona Board Of Regents On Behalf Of Arizona State

Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof

The present invention relates to new immunogenic compositions comprising conjugated streptococcus pneumoniae capsular saccharide antigens (glycoconjugates), kits comprising said immunogenic compositions and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a s.
Pfizer Inc.

Vaccination using plant virus particles linked to her2 antigens

A vaccine composition including a plant virus particle linked to an her2 antigen is described. The vaccine composition can be used for methods of treating or preventing an her2-expressing cancer in a subject by administering to a subject in need thereof an effective amount of the vaccine composition..
Case Western Reserve University

Combination of vaccination and ox40 agonists

The present invention relates to a vaccine/agonist combination comprising an rna vaccine comprising at least one rna comprising at least one open reading frame (orf) coding for at least one antigen and a composition comprising at least one ox40 agonist. The present invention furthermore relates to a pharmaceutical composition and a kit of parts comprising the components of such a vaccine/agonist combination.
Curevac Ag

Swine vaccination system

A system for vaccinating swine according to one embodiment includes a housing having an open first end and an open opposite second end. The housing has a pair of side walls that are angled and non-parallel to one another such that at the second end only a single piglet can exit at one time.
Zoetis Services Llc

Tumors expressing igg1 fc induce robust cd8 t cell responses

A lymphoma cell line was engineered to express surface igg1 fc. These tumor cells were taken up rapidly by dcs, leading to enhanced cross-presentation of tumor-derived antigen to cd8 t cells.
The United States Of America, As Represented By Th E Secretary, Department Of Health And Human Servi

Enhancing the t-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination

We provide new methods of in vitro or in vivo enhancing the t-cell stimulatory capacity of human dcs and the use thereof in cancer vaccination. The method includes the introduction of different molecular adjuvants to human dcs by contacting or modifying them with mrna or dna molecule(s) encoding cd40l, and cd70 or constitutively active tlr4 (catlr4)..
Vrije Universiteit Brussel

Method for the vaccination against hiv

The present invention relates to novel compositions of active agents and methods for the treatment of hiv infection and aids. In particular, the present invention relates to novel methods to select hiv infected patients with improved responses to hiv-specific vaccine peptides..
Bionor Immuno As

Dimethyl fumarate and vaccination regimens

Provided herein is a method of treating or preventing a disease or disorder (e.g., ms) in a subject in need thereof, comprising (a) administering to the subject a first dose of a pharmaceutical composition comprising a fumarate agent (e.g., dmf) for a first dosing period; (b) administering a vaccine; and (c) administering to the subject a second dose of the pharmaceutical composition for a second dosing period.. .
Biogen Ma Inc.

Kidney-specific tumor vaccine directed against kidney tumor antigen g-250

This invention provides an anti-cancer immunogenic agent(s) (e.g. Vaccines) that elicit an immune response specifically directed against renal cell cancers expressing a g250 antigenic marker.
The Regents Of The University Of California

H5 proteins of h5n1 influenza virus for use as a medicament

The present invention is based on the surprising finding that h5 protein of clade 1 h5n1 induces, in particular by a single-shot vaccination, a cross-clade protective immune response to influenza viruses with h5n1 ha. In one aspect, the invention is thus directed to h5 protein of clade 1 h5n1 virus for use in a method of treating or preventing infections with h5n1 virus of a different clade, wherein the h5n1 virus of a different clade comprises a particular polynucleotide and/or h5 protein..
Boehringer Ingelheim Vetmedica Gmbh

Siv and hiv vaccination using rhcmv- and hcmv-based vaccine vectors

Particular aspects provide for use of the β-herpesvirus cytomegalovirus (cmv: e.g., rhcmv and hcmv) as a uniquely evolved “vector” for safely initiating and indefinitely maintaining high level cellular and humoral immune responses (against, e.g., hiv, siv, tb, etc.). Particular aspects provide a method for treatment or prevention of, e.g., hiv, siv or tb, comprising infection of a subject in need thereof with at least one recombinant cmv-based vector (e.g., hcmv or rhcmv) comprising an expressible hiv/siv/tb antigen or a variant or fusion protein thereof.
Oregon Health & Science University

Compositions and methods for immunomodulation in an organism

The present invention relates to a therapeutic polypeptide and methods for its creation and use for modulating an immune response in a host organism in need thereof. In particular, the invention relates to the administration to an organism in need thereof, of an effective amount of a pre-coupled polypeptide complex comprising a lymphokine polypeptide portion, for example il-15 (seq id no: 5, 6), il-2 (seq id no: 10, 12) or combinations of both, and an interleukin receptor polypeptide portion, for example il-15ra (seq id no: 7, 8), il-2ra (seq id no: 9, 11) or combinations of both, for augmenting the immune system in, for example, cancer, scid, aids, or vaccination; or inhibiting the immune system in, for example, rheumatoid arthritis, or lupus.
University Of Connecticut

Service-oriented, integrative networking platform, system and method

In accordance with aspects of the present invention, provided is service-oriented, integrative networking system where a user (e.g., a patient) can have a single profile, single login, meaningful connections through medicine, since every person is a patient at some point in their life and has to see a doctor. A user's profile can be a portal to anything on internet, which allows a user to select connections, have its medical records shared seamlessly with its doctors, and a user can track its appointments, vaccinations, and so on..

Muscle-specific nucleic acid regulatory elements and methods and use thereof

The present invention relates to nucleic acid regulatory elements that are able to enhance muscle-specific expression of genes, in particular expression in cardiac muscle and/or skeletal muscle, methods employing these regulatory elements and uses of these elements. Expression cassettes and vectors containing these nucleic acid regulatory elements are also disclosed.
Universiteit Gent

Targeted gene delivery for dendritic cell vaccination

Methods and compositions are provided for delivery of a polynucleotide encoding a gene of interest, typically an antigen, to a dendritic cell (dc). The virus envelope comprises a dc-sign specific targeting molecule.
California Institute Of Technology

Recombinant low virulence bovine herpesvirus-1 (bohv-1) vaccine vectors

The present disclosure teaches generally in the field of vaccination and disease control in cattle and bovine animals. A recombinant bovine herpesvirus 1 (bohv-1) vaccine vector is provided for efficient control of one or more bovine pathogens such as those associated with bovine respiratory disease complex, such as bovine viral diarrhea virus (bvdv), and which ameliorates disease conditions caused thereby.
Meat & Livestock Australia Limted

Compositions and methods for immunomodulation in an organism

The present invention relates to a therapeutic polypeptide and methods for its creation and use for modulating an immune response in a host organism in need thereof. In particular, the invention relates to the administration to an organism in need thereof, of an effective amount of a pre-coupled polypeptide complex comprising a lymphokine polypeptide portion, for example il-15 (seq id no: 5, 6), il-2 (seq id no: 10, 12)or combinations of both, and an interleukin receptor polypeptide portion, for example il-15ra (seq id no: 7, 8), il-2ra (seq id no: 9, 11) or combinations of both, for augmenting the immune system in, for example, cancer, scid, aids, or vaccination; or inhibiting the immune system in, for example, rheumatoid arthritis, or lupus.
University Of Connecticut

Diagnostic biomarkers and therapeutic targets for pancreatic cancer

We identified >40 proteins that elicited at least a 2-fold increase in antibody response post-pancreatic-cancer vaccination, from each of three patients' sera. The antibody responses detected against these proteins in patients with >3 years disease-free survival indicates the anti-tumor potential of targeting these proteins.
The Johns Hopkins University

Flagellin-containing protein nanoparticles as a vaccine platform

The present invention relates to self-assembling protein nanoparticles constructed from suitable oligomerization domains and further incorporating the tlr5 binding protein flagellin as an adjuvant molecule. Furthermore, the invention relates to the use of such nanoparticles for vaccination..
Alpha-o Peptides Ag

Use of mtor inhibitors to enhance t cell immune responses

It is disclosed herein that treatment of a subject with an mtor inhibitor enhances antigen-specific t cell immune responses. Thus, provided herein is a method of enhancing an antigen-specific t cell response in a subject by administering to the subject a therapeutically effective amount of an mtor inhibitor.
Emory University

Mycobacterium tuberculosis specific peptides for detection of infection or immunization in non-human primates

The present invention relates to novel peptides that may be used in whole or in combination for the detection of mycobacterium tuberculosis infection. In particular, the present invention relates to compositions and methods involving detection of antibodies contained in the blood of non-human primates that arise from an infection from m.
Intuitive Biosciences, Inc.

Methods of treatment of hpv related diseases

The present invention provides methods of mucosal tissue administration of therapeutic hpv vaccines, in a prime-boost regimen, which generated antigen-specific cd8+ t cell-mediated immune responses and the expression of tissue-resident memory t cell (trm) markers on the cd8+ t cells. In some embodiments, the inventive methods employed pngvl4a-sig/e7(detox)/hsp70 dna vaccine and ta-hpv in a prime-boost regimen which shows vaccination in the infected mucosal tissues, including those in the cervicovaginal tract, elicited potent antitumor effects and a more effective local immune response in the tissues and regional lymph node, when compared to intramuscular vaccination.
The Johns Hopkins University

Artificial nucleic acid molecules

The invention relates to an artificial nucleic acid molecule comprising at least one open reading frame and at least one 3′-untranslated region element (3′-utr element) comprising a nucleic acid sequence which is derived from the 3′-utr of a fig4 gene or from a variant of the 3′-utr of a fig4 gene. The invention further relates to the use of such an artificial nucleic acid molecule in gene therapy and/or genetic vaccination.
Curevac Ag

Lipopolysaccharide-targeted peptide mimic vaccine against q fever

A vaccine and method of vaccination for conferring immunity to q fever is described. The vaccine comprises a polypeptide with a sequence of sltwhkhelhrk (m1e41920) or sppwhkhelhrk (m1e44), or at least 90% identity to m1e41920 or m1e44.

Silicon dioxide nanoparticles and the use thereof for vaccination

The invention relates to ultrasmall, monodisperse nanoparticles comprising silicon dioxide to the surface of which at least one antigen is attached. The nanoparticles can be used for the immunoprophylaxis or immunotherapy of cancer.
Merck Patent Gmbh

Compositions and methods for vaccination against influenza a virus

Disclosed herein are compositions and methods useful for immunizing a subject against disease caused by influenza a. Disclosed methods comprise administering to the subject an immunoprotective dose of an immunogenic composition.
South Dakota Board Of Regents

Integration of meningococcal conjugate vaccination

The invention provides a method for immunising a patient, comprising administering multiple conjugates meningococcal capsular saccharides, wherein each conjugate comprises a diphtheria toxoid (or derivative thereof) carrier protein, and the capsular saccharide, and wherein the patient has been pre-immunised with a diphtheria toxoid (or derivative thereof).. .
Glaxosmithkline Biologicals Sa

Hyperblebbing shigella strains

Hyperblebbing shigella strains are generated by disrupting one or more components of the tol-pal system. The blebs from these strains are useful immunogens for vaccination.
Novartis Vaccines Institute For Global Health S.r.l.

Ama-1 epitopes, antibodies, compositions, and methods of making and using the same

Disclosed are ama-1 immunogenic peptides and epitopes, nucleotide sequences encoding the peptides and epitopes, compositions, and vaccines including the peptides and/or epitopes. Antibodies that specifically bind to ama-1 and the ama-1 epitopes and immunogenic peptides disclosed herein are also provided.
The Goverment Of The United States, As Represented By The Secretary Of The Army

Method of inducing the production of protective anti-hiv-1 antibodies

The present invention relates, in general, to an immunogen for hiv vaccination and, in particular, to a method of inducing the production of protective anti-hiv antibodies by targeting b cell germline and clone intermediates using a combination of hiv envelope and non-hiv immunogens. The invention also relates to compositions suitable for use in such a method..
Duke University

Use of acid stable proteases in animal feed, preferably to increase performance of cocc-vaccinated broiler chickens

The invention relates to the use of at least one acid stable protease in poultry feed in combination with anti-coccidial vaccination of birds for increasing the performance of vaccinated animals. It has been found surprisingly that the additions of at least one acid stable protease according to the invention to the diet of “cocci”-vaccinated birds have a significant improvement of animal performance.
Dsm Ip Assets B.v.

Method for generation of immunoglobulin sequences

The present invention relates to a method for generating immunoglobulin sequences against cell-associated antigens, more particularly, antigens that are membrane-anchored. The invention also provides immunoglobulin sequences obtainable by the method of the invention.
Ablynx N.v.

Broadly neutralizing human immunodeficiency virus type 1 (hiv-1) gp120-specific monoclonal antibody

The invention provides a method for obtaining a broadly neutralizing antibody (bnab), including screening memory b cell cultures from a donor pbmc sample for neutralization activity against a plurality of hiv-1 species, cloning a memory b cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory b cell culture. The resultant monoclonal antibodies may be characterized by their ability to selectively bind epitopes from the env proteins in native or monomeric form, as well as to inhibit infection of hiv-1 species from a plurality of clades.
International Aids Vaccine Initiative

Bystander immune suppression as a predictor for response to a vaccine

The present invention relates to antigen-specific immune regulatory response. Methods for detecting an antigen-specific immune regulatory response, methods for selecting candidate vaccine recipients, and methods for improved vaccination strategies are presented..
Wisconsin Alumni Research Foundation

Influenza vaccine for skin immunization

A method for preventing, treating or reducing the effects of influenza infection in a subject by administering an influenza vaccine to the skin of the subject. The administration can be intradermal or by microneedle patch.
Sporos Therapeutics, Llc

Apparatus, system, and secure and comfortable animal enclosure

An apparatus, system, and method are disclosed for a secure and comfortable animal enclosure providing convenient automated access and payment with validated user identification and validated animal identification linked to the animal's vaccinations and health records and configured for use in or near business, commercial, entertainment, workplace and other venues.. .

Adjuvanted vaccines for in ovo avian vaccination

A composition includes at least one mineral oil, a surfactant having a hydrophilic property characterised by an hlb value equal to 12 and a divalent inorganic salt intended to be used as an adjuvant in a vaccine composition for the in ovo vaccination of avian species wherein the composition is an oil-in-water emulsion or microemulsion.. .
Societe D'exploitation De Produits Pour Les Industries Chimiques Seppic

Use of a lipopeptide or lipoprotein as an adjuvant in therapeutic or prophylactic vaccinations

Disclosed is the use of lipopeptides and lipoproteins as mucosal adjuvants for various vaccinations via mucous membranes, particularly intranasally. Said lipopeptides represent peptides or proteins substituted with 2,3-diacyloxy(2r)-propyl at the amino-terminal cystein of a peptide or protein, preferably s-(2,3-bis-palmitoyloxy-(2r)-propyl)cysteinyl peptides derived from mycoplasmas.

Influenza vaccine

The present invention relates to monovalent influenza vaccine formulations and vaccination regimes for immunising against influenza disease, their use in medicine, in particular their use in augmenting immune responses to various antigens, and to methods of preparation. In particular, the invention relates to monovalent influenza immunogenic compositions comprising an influenza antigen or antigenic preparation thereof from an influenza virus strain being associated with a pandemic outbreak or having the potential to be associated with a pandemic outbreak, in combination with an oil-in-water emulsion adjuvant comprising a metabolisable oil, a sterol and/or a tocopherol such as alpha tocopherol, and an emulsifying agent..
Glaxosmithkline Biologicals Sa



Vaccination topics:
  • Vaccination
  • Immune Response
  • Immunogenic
  • Antibodies
  • Gene Therapy
  • Stimulator
  • Infectious Diseases
  • Infectious Disease
  • Infectious
  • Nucleotide
  • Biopolymer
  • Oligonucleotide
  • Oligopeptide
  • Sequencing
  • Alkylation


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Vaccination for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Vaccination with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.2855

    file did exist - file did put2446

    3 - 1 - 52